· Published by Health Canada · Official notice
This is duplicated text of a letter from Merck Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 13, 2012
Subject: ZOCOR® (simvastatin) - New Safety Recommendations on Dosage Associated with the Increased Risk of Muscle Problems
Merck Canada Inc., in consultation with Health Canada, would like to inform you of important safety recommendations on dosage related to the increased risk of muscle problems, particularly with the 80 mg dose of ZOCOR® (simvastatin; also marketed as generics). An increased risk of muscle problems within the recommended dose range for ZOCOR® (simvastatin) can also be seen when taken with certain other medicines.
ZOCOR® is used to lower the levels of cholesterol and fatty substances called triglycerides in blood and to reduce the health risks associated with coronary heart disease.
Since the administration of ZOCOR® (simvastatin) with many other drugs can increase the risk of muscle problems, it is particularly important to tell your physician if you are taking any drugs prior to starting ZOCOR® (simvastatin). While taking ZOCOR®(simvastatin) you should avoid drinking large quantities of grapefruit juice (more than 1 liter daily).
Merck Canada has sent a letter to healthcare professionals informing them of this new safety information. Further information may be obtained on the Merck Canada product information Web site or on the Health Canada Web site. If you have any questions regarding your ZOCOR® prescription, contact your doctor.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious muscle problems or other serious or unexpected side effects in patients receiving ZOCOR® should be reported to Merck Pharmacovigilance or Health Canada.
Merck Canada Inc., Pharmacovigilance
16750 Trans-Canada Hwy.
Kirkland, Québec H9H 4M7
Fax: 1-800-369-3090
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit theMedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Mauricio Ede, M.D.
Medical Director, Medical Affairs
® Registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.Used under license.